Cancer

iStock/CIPhotos

Merck boosts cancer pipeline in €464m deal

By Flora Southey

Merck & Co has announced it will acquire immunotherapy-focused Rigontec and lead candidate RGT100, designed to treat patients with solid tumours and lymphoma.